On July 20, 2020, the United States Food and Drug Administration (FDA) announced a six-month extension of its enforcement discretion policy for certain regenerative medicine products requiring pre-market review due to the COVID-19 pandemic. Included in a final guidance document entitled, “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use,” this extension will give manufacturers additional time to determine whether they need to submit an investigational new drug (IND) or marketing ...
Blog Editors
Recent Updates
- A Step Closer to the Proposed End of the Self-Affirmed GRAS Pathway
- Imports and the DOJ’s Trade Fraud Task Force: Considerations for the Health Care and Life Sciences Industries
- Federal Appellate Court Upholds Mississippi 340B Contract Pharmacy Protections
- DOJ False Claims Act Priorities: Cybersecurity Is Still on the Radar
- DOJ Launches Cross-Agency Trade Fraud Task Force: What Importers and Businesses Need to Know